Apogee Therapeutics

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.

Developer of an antibodies experimental platform designed to empower biological antibodies and other therapeutic proteins. The company's platform is agile, multi-objective, and data-driven and integrates a wet laboratory with artificial intelligence and machine learning techniques to design antibodies, enabling drug developers to create antibodies and undertake novel biotherapeutic designs.

Developer of therapeutic human monoclonal antibodies designed to offer treatment of cancer and infectious diseases. The company's human monoclonal antibodies and antibody discovery platform couples proprietary knowledge of B cell immortalization with the isolation of promising antibodies from humans or animals, enabling healthcare organizations to provide patients with quality care in a cost-efficient manner.